Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
abate, ABIM, Acumen, add, addendum, Aldeyra, alliance, Anne, Aon, Asia, asymptomatic, Athira, attention, attrition, Australia, background, benchmark, Bernardo, bid, BioLine, Biopharma, blend, Brazilian, breakdown, Bribery, capable, Caspi, chair, Chamonix, Chancery, Chicago, choose, Clinician, cohesive, College, Collplant, Colombia, complaint, Compugen, confirmatory, consortium, constitutionality, Corrupt, counsel, cyber, cyberattack, damage, delisted, delisting, Deloitte, departure, depressing, Derovan, devoting, Diasome, difficulty, discontinue, discontinued, dismissed, drop, dropout, dropped, EASD, Edge, electrical, Eliem, engineering, Enlivex, Enochian, EU, fatigue, fewer, fluid, fold, FRCP, Gamida, Gel, GoldenTree, Goldfarb, goodwill, Guaranty, guide, guideline, gym, hand, Head, headed, Houssay, ID, identical, immune, immunogenicity, imperative, inappropriate, inconclusive, incurrence, Indonesia, injury, inside, intrusion, JDRF, Kamada, Kazakhstan, Keck, Korea, Laureate, LLB, Malaysia, malware, media, Medicox, Mexico, Midwest, mild, morale, Netanel, noncompliance, nonpublic, Northwestern, notwithstanding, occasion, offsite, Oman, optimal, Optum, Panel, Pennsylvania, penny, Pharma, plaintiff, PolyPid, possession, predominant, presence, Pritzker, pro, promising, proven, qualitative, Rallybio, rata, Redhill, regain, remeasured, replicate, replicated, Repositioning, reproduce, reputation, reputational, residency, revaluation, round, Rozov, Russia, rx, SAPHRA, satisfactorily, Seligman, Shnida, side, Singapore, slower, Society, Sol, sophistication, Southeast, Southern, speculation, Stanford, stemming, summa, Supreme, Switzerland, Syncora, Tan, telecommunication, Terrace, Thailand, Thanh, top, trademark, trend, Turkey, UBS, UCLA, Ukraine, unanticipated, undertaken, unified, unintended, Union, upheld, Urogen, USC, Uzbekistan, Velocity, Verastem, vi, viability, viable, Vietnam, view, viewed, vii, viii, Viking, VistaGen, VLP, vulnerable, war, weaker, Werewolf, Wharton, workplace, worthwhile, writing, wrongdoing, Yadin, Zomedica
Removed:
absence, acquirer, adjustment, affiliated, aggregated, Ariel, arm, Avraham, BioHealing, bloodstream, Commerce, complement, concept, consumer, DeFronzo, deploying, Diaspora, Discouraging, discrepancy, effort, Emisphere, enable, excellent, extension, flagship, FPG, frequency, Gabay, Gao, glucagon, graduate, Green, HighCape, hypoglycemic, IIb, Impeding, incretin, Incubation, inflammatory, innovator, interaction, investigate, Investigational, Jersey, joining, knowledgeable, leptin, likelihood, Maayan, merger, mineral, Minister, MMTT, modest, move, MSA, Nevada, NIH, nonalcoholic, NY, opposite, overview, partnering, passage, pediatric, pharmacokinetic, physiological, plc, Point, portal, PPG, premier, Prime, proof, Rahway, recommended, recruited, Regenerative, reincorporated, remining, rest, resulted, revolutionizing, Rhythmia, Rosetta, secretion, select, Sharon, Shire, significance, statistically, substantiate, takeover, tender, thrice, tiered, titrated, tolerance, tract, treated, twelve, undergraduate, undiluted, vein, Xiaoming
Filing tables
Filing exhibits
- 10-K Annual report
- 4.4 Description of Securities
- 10.1 Consulting Agreement by and Between Oramed Pharmaceuticals Inc. and Shnida LTD., Entered into As of November 1, 2022, for the Services of Nadav Kidron
- 10.2 Employment Agreement by and Between Oramed LTD. and Nadav Kidron, Entered into As of November 1, 2022
- 10.13 Second Amendment, Dated October 25, 2022, to Employment Agreement, by and Between Oramed LTD. and David Silberman
- 10.14 Representative Form of Indemnification Agreements Between Oramed Pharmaceuticals Inc. and Each of Our Directors and Officers
- 10.23 Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement
- 10.41 Oravax Medical, Inc. 2021 Long-term Incentive Plan
- 10.42 Oravax Stock Option Agreement
- 23.1 Consent of Kesselman & Kesselman, Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
ORMP similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Nadav Kidron, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 6, 2023 | By: | /s/ Nadav Kidron |
Nadav Kidron | ||
President and | ||
Chief Executive Officer |